Charles River Laboratories International, Inc.
CRLAction· NYSE· USD
L'essentiel à retenir
- • Dernier cours : 286,83 $US (cours différé)
- • Variation sur 1 an : +63,57 %
- • Type d'actif : Action
- • Place de cotation : NYSE
- • Devise de cotation : USD
- • Clôture précédente : 295,01 $US
Informations
- Symbole
- CRL
- Type
- Action
- Place
- NYSE
- Devise
- USD
- Clôture veille
- 295,01 $US
- Variation 1 an
- +63,57 %
Animal Model - Global Strategic Business Report: Market Size to Surge to $3.6 Billion by 2032 as CRISPR Disrupts R&D - Benchmark Charles River, Biocytogen, Crown Bioscience, Cyagen and The Jackson Laboratory
Animal model demand is rising with drug and vaccine research. CRISPR, AI and humanized models offer opportunities, while ethical scrutiny spurs humane alternatives.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Animal Model - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global animal model market was estimated at US$2.1 billion in 2025 and is projected to reach US$3.6 billion by 2032, advancing at a compound annual growth rate (CAGR) of 7.9%. Market exp
Yahoo Finance · 30/09/2026 · lire l'article ↗
Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery
Cooke & Bieler, an investment management firm, released its second-quarter investor letter for “Mid Cap Value Equity Strategy.” The letter can be downloaded here. U.S. equities rallied significantly in Q2, driven by shifting geopolitical risks and strong investor appetite for high-beta stocks, particularly in the tech sector, contributing to the S&P 500® and Nasdaq’s best […]
Yahoo Finance · 29/09/2026 · lire l'article ↗
Pharmaceutical Impurity Synthesis and Isolation Services Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cambrex and Charles River
Stricter quality rules, complex biologics and outsourcing are driving demand for impurity isolation, synthesis and analytics, creating opportunities for specialized labs and CROs.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Pharmaceutical Impurity Synthesis and Isolation Services - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global pharmaceutical impurity synthesis and isolation services market was valued at US$1.3 billion in 2024 and is projected to
Yahoo Finance · 29/09/2026 · lire l'article ↗
Computer-Aided Drug Discovery - Global Strategic Business Report: Capitalize on 11% CAGR as AI-led CADD surges from $3.2B in 2025 to $6.7B by 2032—benchmark Bayer, Charles River Laboratories, Pharmaron and Chemical Computing Group to secure growth.
AI, machine learning, cloud analytics and multi-omics are accelerating drug discovery, enabling targeted, personalized therapies while reducing development time, cost and risk.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Computer-Aided Drug Discovery - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global computer-aided drug discovery market was estimated at US$3.2 billion in 2025 and is projected to reach US$6.7 billion by 2032, expanding at a compound
Yahoo Finance · 29/09/2026 · lire l'article ↗
NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs
Engagement of a leading global contract research organization strengthens the analytical foundation supporting EL-22 and EL-32 as the programs advance toward an IND-enabling development frameworkBuilds on NorthStrive Biosciences’ expanding manufacturing and characterization capabilities behind its engineered probiotic platform targeting muscle preservation, including for patients on GLP-1 weight loss treatments NEWPORT BEACH, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq:
Yahoo Finance · 29/09/2026 · lire l'article ↗
Global Experimental Animal Model Market Outlook and Forecast, 2026-2032 - AI-Enabled Research and Advanced Transgenic and Oncology Models Drive 9.18% CAGR Toward US$2.23 Billion, With Charles River, The Jackson Laboratory, Taconic Biosciences and Crown Bioscience Profiled
Boost ROI by matching models to research goals, standardizing studies, investing in quality data and training, integrating validated AI and alternatives, and aligning global partnershipsDublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Experimental Animal Model Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. This market research report examines the global Experimental Animal Model Market, which is projected to reach USD 1.31 billion in 2026 and expand at a comp
Yahoo Finance · 29/09/2026 · lire l'article ↗
Titres et résumés fournis par les sources d'origine (flux Yahoo Finance). Cliquez pour lire l'article complet.
Questions fréquentes sur Charles River Laboratories International, Inc.
- Quel est le cours actuel de Charles River Laboratories International, Inc. ?
- Le dernier cours connu de Charles River Laboratories International, Inc. (CRL) est de 286,83 $US (cours différé, fourni à titre informatif). Cette page est mise à jour régulièrement.
- Quelle est la performance de Charles River Laboratories International, Inc. sur un an ?
- Sur les 12 derniers mois, Charles River Laboratories International, Inc. (CRL) affiche une variation de +63,57 %. Les performances passées ne préjugent pas des performances futures.
- Comment suivre Charles River Laboratories International, Inc. dans mon portefeuille ?
- Créez un compte gratuit sur AssetApp, ajoutez CRL à l'un de vos portefeuilles et suivez sa valeur, vos plus-values et son actualité — aux côtés de vos autres actifs.
Actifs similaires
Charles River Laboratories International, Inc. : suivre cet actif
Charles River Laboratories International, Inc. (CRL) est une action coté sur NYSE en USD. Avec AssetApp, ajoutez CRL à votre portefeuille pour suivre sa valeur, vos gains latents et réalisés, et l'évolution de votre patrimoine — sans dépendre de votre courtier.
Suivre CRL gratuitement